Roche-backed biotech refuels with $40M to steer neuromuscular candidate toward late-stage trials

Four years after receiving backing from Roche to see if it can carve out a unique path in rare neuromuscular disorders, Aarhus, Denmark-based NMD Pharma has reloaded with almost $40 million (€35 million) to continue on it.